Document is current

Article History

Received: 5 August 2022

Accepted: 19 August 2022

First Online: 8 September 2022

Declarations

:

: MSc received honoraria for CME presentations from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis; research funding to institution from AstraZeneca, Bristol Myers-Squibb; consultancy (compensated): Amgen, AstraZeneca, BIOCAD, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda. SK received honoraria from Merck Serono, MSD, Novartis, BMS, Amgen, Roche, Sanofi-Aventis, Servier, Incyte and Lilly; research funding from Merck Serono, Lilly, BMS, Roche. JS reports the following disclosures: Bristol Myers Squibb, Celgene, Roche (Research Funding); AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol Myers Squibb, Celgene, Falk Foundation, Iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 (< 3%) and member of the Board of Directors for Pharma15, all outside the submitted work. VR received travel support from AbbVie and AstraZeneca. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Local Ethics Committee of the Medical Faculty of the University Duisburg-Essen (No. 17–7472-BO).

: In this retrospective study, data were anonymized. Therefore, informed consent from all individual participants was not necessary according to the institutional requirements.

: Not applicable.